ArticleScientific reports2025
"5,7,4'-trimethoxyflavanone from Bauhinia variegata exerts anti‑inflammatory and protective actions in LPS‑challenged rat intestine".
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Piceatannol ameliorates intestinal barrier dysfunction in urosepsis by modulating the Nrf2/ROS/NF-κB pathway.Scientific reports · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
This study aimed to investigate the protective effects of 5,7,4'-trimethoxyflavanone (TMF), a bioactive compound isolated from Bauhinia variegata Linn., on lipopolysaccharide (LPS)-induced intestinal injury in rats. Chronic intestinal inflammation was induced by repeated LPS administration, and the therapeutic potential of TMF in alleviating the associated damage was assessed. Male rats were subjected to chronic intestinal inflammation via repeated intraperitoneal administration of LPS at a dose of 1 mg/kg body weight once daily for 4 weeks. Simultaneously, the test group received daily oral administration of TMF at 75 mg/kg body weight from day one after 4 weeks of induction of intestinal inflammation until the end of the experiment. Histopathological examination of the intestines, along with biochemical assays for inflammatory markers, oxidative stress, and tissue integrity, were performed to evaluate the protective effects of TMF. Comparisons between the LPS-treated control group and the TMF-treated group were made to assess the reductions in inflammation and intestinal injury. TMF therapy diminished LPS-induced Nuclear Factor kappa B(NF-κB) activation and inhibited the levels of TNF-α, IL-6, and IL-1β, thereby reducing oxidative stress. These data indicate that TMF provides protective effects by regulating critical inflammatory and oxidative processes associated with LPS-induced intestinal damage. In conclusion, TMF from B. variegata has been demonstrated to be a potential therapeutic agent for mitigating intestinal inflammation and oxidative damage, suggesting a natural method for addressing inflammation-induced gut lesions. Additional research is necessary to investigate its clinical applicability in inflammatory bowel disease and other gastrointestinal conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.